Infantile NO Replenishment as a New Therapeutic Possibility

Launched by NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS · Jun 3, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Infantile NO Replenishment as a New Therapeutic Possibility," is looking at how a treatment called inhaled Nitric Oxide (iNO) may help infants who are born too early (premature) or those who are born full-term but still need breathing support. The main goal is to understand how this treatment affects the health of these infants as they grow, focusing on their development in areas like hormone function and overall health.

To be part of this study, infants must be receiving respiratory support and be admitted to a Neonatal Care Unit. This includes both preterm infants (born before 37 weeks of pregnancy) and full-term infants (born at 37 weeks or later). However, infants with serious birth defects or those considered nonviable by their doctor won’t be eligible. If your child qualifies and participates, they will receive the prescribed iNO treatment, and researchers will monitor their progress to see how it impacts their growth and development. This study is currently recruiting participants, and all genders from ages 1 to 21 are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Preterm (GA\<37 weeks) or full-term (≥37 weeks of gestation) infants
• • Requiring respiratory support
• • Admitted to Neonatal Care Unit
• Exclusion Criteria:
• • Severe congenital anomalies
• • Suspected major chromosomal anomalies
• • Infants judged by the physician as nonviable